Zhejiang Jolly PharmaceuticalLTD Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Zhejiang Jolly PharmaceuticalLTD.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	19.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Aug 30

We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Jul 29

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Mar 01

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zhejiang Jolly PharmaceuticalLTD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300181 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	2,359	481	245	381	N/A
3/31/2024	2,120	428	145	294	N/A
12/31/2023	1,942	383	157	288	N/A
9/30/2023	1,926	356	162	349	N/A
6/30/2023	1,922	336	137	310	N/A
3/31/2023	1,861	302	91	245	N/A
1/1/2023	1,805	273	141	319	N/A
9/30/2022	1,723	252	58	260	N/A
6/30/2022	1,655	228	75	290	N/A
3/31/2022	1,557	204	74	290	N/A
1/1/2022	1,457	179	104	252	N/A
9/30/2021	1,400	158	234	319	N/A
6/30/2021	1,322	145	269	336	N/A
3/31/2021	1,238	122	267	327	N/A
12/31/2020	1,091	89	221	280	N/A
9/30/2020	1,024	49	180	222	N/A
6/30/2020	949	29	82	118	N/A
3/31/2020	901	26	112	148	N/A
12/31/2019	911	26	88	129	N/A
9/30/2019	859	34	109	160	N/A
6/30/2019	767	14	39	131	N/A
3/31/2019	764	23	-5	104	N/A
12/31/2018	730	21	-76	78	N/A
9/30/2018	609	20	-125	36	N/A
6/30/2018	629	31	-41	102	N/A
3/31/2018	647	43	N/A	20	N/A
12/31/2017	679	45	N/A	8	N/A
9/30/2017	804	49	N/A	114	N/A
6/30/2017	814	63	N/A	21	N/A
3/31/2017	830	59	N/A	54	N/A
12/31/2016	840	72	N/A	58	N/A
9/30/2016	819	86	N/A	22	N/A
6/30/2016	810	87	N/A	78	N/A
3/31/2016	720	85	N/A	112	N/A
12/31/2015	671	85	N/A	97	N/A
9/30/2015	657	103	N/A	16	N/A
6/30/2015	620	111	N/A	-18	N/A
3/31/2015	572	107	N/A	-39	N/A
12/31/2014	515	103	N/A	14	N/A
9/30/2014	457	94	N/A	13	N/A
6/30/2014	440	90	N/A	35	N/A
3/31/2014	431	85	N/A	42	N/A
12/31/2013	419	81	N/A	30	N/A
9/30/2013	401	75	N/A	8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300181's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if 300181's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300181's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300181's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300181's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300181's Return on Equity is forecast to be high in 3 years time

Zhejiang Jolly PharmaceuticalLTD Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.14 in 2Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) announces an Equity Buyback for CNY 300 million worth of its shares.

We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Now 21% undervalued after recent price drop

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2024 Results on Jul 30, 2024

New minor risk - Share price stability

Dividend increased to CN¥0.45

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 1Q 2023)

Zhejiang Jolly Pharmaceutical Co.,LTD, Annual General Meeting, May 10, 2024

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Q1, 2024 Results on Apr 19, 2024

Investor sentiment improves as stock rises 18%

Now 22% overvalued after recent price rise

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Investor sentiment deteriorates as stock falls 16%

Insufficient new directors

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.11 in 2Q 2022)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2023 Results on Aug 09, 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Cash Dividend for 2022

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings released: EPS: CN¥2.25 (vs CN¥0.29 in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.074 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.07 in 2Q 2021)

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 31 May 2022

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Cash Dividend for 2021

High number of new and inexperienced directors

Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Zhejiang Jolly Pharmaceutical Co.,LTD announced that it expects to receive CNY 910 million in funding

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.074 (vs CN¥0.052 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.033 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Zhejiang Jolly Pharmaceutical Co.,Ltd Announces Final Cash Dividend for 2020, Payable on 31 May 2021

Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.15 (vs CN¥0.042 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥6.86

Full year 2020 earnings released: EPS CN¥0.14 (vs CN¥0.042 in FY 2019)

Zhejiang Jolly Pharmaceutical Co.,LTD to Report Fiscal Year 2020 Results on Apr 13, 2021

Zhejiang Jolly Pharmaceutical Co.,LTD Approves Management Appointments

Investor sentiment improved over the past week

New 90-day low: CN¥5.87

New 90-day low: CN¥6.12

New 90-day low: CN¥6.59

Third quarter earnings released

New 90-day high - CN¥8.10

Zhejiang Jolly Pharmaceutical Co.,LTD to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥6.39

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies